乳腺癌患者抗癌疗法诱导的微血管功能障碍的特征支持有针对性的干预
Janée D Terwoord1,2, Laura E Norwood Toro1, Shelby N Hader1
1Cardiovascular Center, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
像多克索鲁比辛和特拉斯图祖马布这样的抗癌疗法会在乳腺癌患者中引起持久的微血管内皮功能障碍. 向的VEGF-B干预措施在保护这种化疗诱导的血管毒性方面显示出希望.
科学领域:
- 心血管研究研究心血管研究
- 在瘤学瘤学.
- 血管生物学 血管生物学
背景情况:
- 心脏毒性是抗癌疗法 (CTx) 的重要并发症.
- 对于CTx对微循环的影响仍然不太了解.
- 这项研究调查了CTx对乳腺癌 (PwBC) 患者微血管功能的影响.
研究的目的:
- 在PwBC中评估CTx对微血管功能的影响.
- 评估PwBC中的内皮功能和血管生成潜力.
- 检查VEGF-B对化疗引起的血管毒性的保护作用.
主要方法:
- 从CTx接受PwBC的动脉小板和脂肪活检中评估了内皮功能和血管生成潜力.
- 暴露于多克索鲁比辛 (Dox),特拉斯图祖马布 (TZM) 或帕克利塔克塞尔 (PTX) 的健康动脉小管.
- 利用VEGF-B蛋白来测试针对性干预的可行性.
主要成果:
- Dox和/或TZM治疗导致严重的,持续的微血管内皮功能障碍 (治疗后≥9个月).
- 在CTx期间血管生成潜力下降,在1个月内恢复.
- 活体Dox或TZM暴露在健康的动脉小管中诱导了内皮功能障碍;PTX没有影响.
- 在暴露于Dox或TZM的动脉小管中,VEGF-B蛋白保留了内皮功能.
结论:
- 用Dox和/或TZM治疗的PwBC经历了长时间的微血管内皮功能障碍.
- 这种功能障碍可以在暴露于Dox或TZMex vivo的健康人体动脉小动脉中复制.
- 向的VEGF-B干预可以防止Dox或TZM诱导的人类动脉小动脉中的血管毒性.
更多相关视频
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Drugs that Stabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Destabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
